Australia markets closed

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
23.51-0.31 (-1.30%)
At close: 04:00PM EDT
23.51 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close23.82
Open23.66
Bid23.50 x 100
Ask23.56 x 200
Day's range23.31 - 23.82
52-week range20.87 - 34.28
Volume401,678
Avg. volume1,350,749
Market cap2.441B
Beta (5Y monthly)0.48
PE ratio (TTM)25.01
EPS (TTM)0.94
Earnings date01 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est42.80
  • Zacks

    Corcept (CORT) Completes Enrollment in Ovarian Cancer Study

    The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.

  • GlobeNewswire

    Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

    MENLO PARK, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in ROSELLA, a pivotal Phase 3 trial of its proprietary selective cortisol modulator relacorilant combined with nab-paclitaxel in patients with

  • GlobeNewswire

    Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

    MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in GRADIENT, a Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with Cushing’s syndrome (hypercortisolis